Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.
|Slideshows|May 31, 2018
New FDA Warning
Author(s)James Phelps, MD
A rare but serious reaction to this treatment can have immunological consequences. As with all medications, however, the latest alert does not change how psychiatrists manage the risks.
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Psychiatric Times
1
Assessing Interventions for Insomnia in Peri- and Postmenopausal Women
2
Food Noise and GLP-1 Drugs: What Research Reveals About Motivation and Appetitive Drive
3
ALKS 7290 for Adjunctive Treatment for MDD Enters Phase 2 Study
4
October 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
5